ArticleMicroorganisms2023
Evaluation of Febrile Neutropenia in Hospitalized Patients with Neoplasia Undergoing Chemotherapy.
Article in Microorganisms, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Real-world evidence from a tertiary academic center: clinical characteristics, microbiology and outcomes of oncology patients with febrile neutropenia presenting to the emergency department.BMC infectious diseases · 2026Article
- Enhanced detection of sepsis pathogens in hospitalized febrile neutropenia patients using blood culture broths with TaqMan array card.Research square · 2026Article
- Chemotherapy-Induced Myelosuppression in Patients With gBRCA-m Epithelial Ovarian Cancer: A Retrospective Study.Cancer medicine · 2026Article
- The impact of neutropenia severity in the setting of recent chemotherapy on mortality in sepsis.International journal of clinical oncology · 2026Article
- Incidence and risk factors of infections in lung cancer patients receiving immunotherapy combined with chemotherapy: a real-world retrospective study.American journal of cancer research · 2026Article
- Low HALP Score Predicts Prolonged Hospitalization in Solid Tumor Patients with Febrile Neutropenia.Current oncology (Toronto, Ont.) · 2025Article
- Microbiological profile and 30-day mortality outcomes in febrile neutropenia among solid malignancy patients: a multicentre retrospective study from resource-limited setting.Scientific reports · 2025Article
- Factors influencing hospital length of stay in febrile neutropenia: A retrospective cohort study of Turkish patients with solid tumors.Medicine · 2025Observational
- Do We Need Meropenem Treatment Beyond 7 Days in Febrile Neutropenic Patients: A Cost-Effectiveness Analysis.Antibiotics (Basel, Switzerland) · 2025Article
- Article
- Parallel Toxicities: A Comparative Analysis of Chemotherapy-Induced Neutropenia and Alopecia.Cancers · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Febrile neutropenia (FN) is a common but serious complication encountered in patients with cancer and is associated with significant morbidity and mortality. In this prospective study, 63 patients with solid tumors under chemotherapy or immunotherapy were admitted to the hospital due to febrile neutropenia, confirmed through clinical or microbiological documentation. The aim of this study was to provide a comprehensive overview of the epidemiological and microbiological characteristics of hospitalized neutropenic patients with solid tumors undergoing treatment. Additionally, we aimed to assess the duration of neutropenia and identify factors influencing patient outcomes. The median age of patients was 71 ± 10.2 years, most of which were males (66.7%), and the primitive tumor location was the lung (38.1%), with most patients (82.5%) being at disease stage IV. The median duration of neutropenia was three days (range 1-10), and, notably, mucositis was significantly associated with neutropenia lasting ≥3 days (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.